BriaCell Therapeutics Stock (NASDAQ:BCTX)
Previous Close
$1.01
52W Range
$0.46 - $6.16
50D Avg
$0.70
200D Avg
$2.20
Market Cap
$29.48M
Avg Vol (3M)
$4.72M
Beta
1.83
Div Yield
-
BCTX Company Profile
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
BCTX Performance
Peer Comparison
Ticker | Company |
---|---|
XFOR | X4 Pharmaceuticals, Inc. |
MREO | Mereo BioPharma Group plc |
DAWN | Day One Biopharmaceuticals, Inc. |
PDSB | PDS Biotechnology Corporation |
HOOK | HOOKIPA Pharma Inc. |
TERN | Terns Pharmaceuticals, Inc. |
INZY | Inozyme Pharma, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
ELEV | Elevation Oncology, Inc. |